Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240
Richard S. Finn(University of California, Los Angeles), Ann‐Lii Cheng(National Taiwan University), Ho Yeong Lim(CHA University Bundang Medical Center), В. В. Бредер, Yee Chao(National Cancer Center), Masatoshi Kudo(Kindai University), Stephen L. Chan(Chinese University of Hong Kong), A.B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States)), Baek‐Yeol Ryoo(Asan Medical Center), Thomas Yau(Queen Mary Hospital), Bruno Daniele(Azienda Ospedaliera G.Rummo), Marcelo Garrido(Pontificia Universidad Católica de Chile), Jennifer J. Knox(National Cancer Center), Julien Edeline(Inserm), E. Chen(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mohamed Bouattour(Hôpital Beaujon), Andrew X. Zhu(Icahn School of Medicine at Mount Sinai), Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sadahisa Ogasawara(Chiba University), Philippe Merle(Hôpital de la Croix-Rousse)
Cited by 11
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k